1-3 of 3
Thomas Hentrich
Close
Sort by
Journal Articles

The Rorɣ/SREBP2 Pathway Is a Master Regulator of Cholesterol Metabolism and Serves As Potential Therapeutic Target in T(4;11) Leukemia

Estelle Erkner, Thomas Hentrich, Rahel Fitzel, Hildegard Keppeler, Fulya Korkmaz, Johan Jeong, Julia Schulze-Hentrich, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind
Journal: Blood
Blood (2022) 140 (Supplement 1): 2999–3000.
https://doi.org/10.1182/blood-2022-169267
Published: 2022
Journal Articles

Inhibition of DOT1L and PRMT5 Promotes Anti-Tumor Activity in a Human MLL Leukemia Model Induced By CRISPR/Cas9

Kathy-Ann Secker, MSc, Hildegard Keppeler, Silke Duerr-Stoerzer, Hannes Schmid, MSc, Dominik Schneidawind, MD, Thomas Hentrich, PhD, Julia Schulze-Hentrich, PhD, Barbara Mankel, Falko Fend, MD, Lothar Kanz, Corina Schneidawind, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5147.
https://doi.org/10.1182/blood-2018-99-115975
Published: 2018
Journal Articles

Myc Drives MLL Leukemogenesis in a Human CRISPR/Cas9 Leukemia Model and Indirect Inhibition with JQ1 Diminishes Leukemia Activity

Kathy-Ann Secker, MSc, Hildegard Keppeler, Silke Duerr-Stoerzer, Hannes Schmid, MSc, Dominik Schneidawind, MD, Thomas Hentrich, PhD, Julia Schulze-Hentrich, PhD, Lothar Kanz, Corina Schneidawind, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2213.
https://doi.org/10.1182/blood-2018-99-114419
Published: 2018